Cross-Reactivity of Antibodies in Intravenous Immunoglobulin Preparation for Protection against SARS-CoV-2

• Published in: Microorganisms Vol. 11; no. 2; p. 471
• Main Authors: Osaka, Toshifumi, Yamamoto, Yoko, Soma, Takehisa, Yanagisawa, Naoko, Nagata, Satoru
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 13.02.2023; MDPI
• Subjects: ACE2; Angiotensin-converting enzyme 2; Antibodies; antibody-dependent enhancement; Antigens; Biology (General); blood; Cellulose acetate; Coronaviruses; COVID-19; COVID-19 infection; COVID-19 vaccines; cross reaction; Cross reactions (Immunology); cross-reactive antibody; Cross-reactivity; Dosage and administration; Enzymes; Guillain-Barre syndrome; health care workers; humans; immunoglobulin; Immunoglobulin G; Immunoglobulins; Immunological research; Infections; Infectious diseases; Intravenous administration; intravenous injection; labor; Low concentrations; Medical personnel; Pandemics; Pneumonia; Proteins; Pseudovirus; pseudovirus entry assay; QH301-705.5; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Spike protein; Testing; Vaccine development; Viral diseases; viruses; Japan; United Kingdom > UK; United States > US; cross-reactive antibody; pseudovirus entry assay; SARS-CoV-2; immunoglobulin; antibody-dependent enhancement

Severe cases of COVID-19 continue to put pressure on medical operations by prolonging hospitalization, occupying intensive care beds, and forcing medical personnel to undergo harsh labor. The eradication of SARS-CoV-2 through vaccine development has yet to be achieved, mainly due to the appearance o...